L-(+)-tartrate salts of cabozantinib and solid forms thereof
Cabotinib was solved by mixing cabotinib with tetrahydrofuran and water at a specific temperature and adding L-(+)-tartaric acid to prepare a solid form of cabotinib L-(+)-tartrate at a specific temperature, and the solid form of cabotinib was prepared. The problem of insufficient solubility and stability of salts has achieved good crystallinity and low hygroscopicity, significantly improving the bioavailability of the drug.
Patent Information
- Application Number
- CN202380031079.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-01
- Filing Date
- 2023-02-28
- Publication Date
- 2024-11-15
AI Technical Summary
The existing cabotinib salt has poor solubility, crystallinity and stability, and its solid form needs to be improved to improve the bioavailability and stability of the drug.
Cabotinib L-(+)-tartaric acid with good crystallinity and improved solubility was prepared by reacting cabotinib with a mixture of tetrahydrofuran, water and L-(+)-tartaric acid within a specific temperature range to prepare cabotinib L-(+)-tartaric acid with good crystallinity and improved solubility The solid form includes specific preparation steps such as mixing, cooling, addition of tartaric acid and drying.
The prepared solid form of cabotinib L-(+)-tartrate showed good crystallinity and low hygroscopicity, significantly improved its solubility, and solved the poor solubility and stability of cabotinib salt in the prior art. A problem of insufficient.
Smart Images

Figure CN118974017A_ABST
Abstract
Description
[0001] The present invention relates to a solid form of L-(+)-tartrate of cabozantinib and a method for preparing the same. Background of the Invention
[0003] The present invention relates to L-(+)-tartrate of cabozantinib, its solid form and preparation method thereof. Cabozantinib, N-[4-(6,7-dimethoxyquinolin-4-yloxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, a compound of formula (1),
[0004]
[0005] Cabozantinib is an orally bioavailable antineoplastic agent approved for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Cabozantinib is marketed in the form of L-malate.
[0006] Cabozantinib was first disclosed in WO2005030140 application. The malate salt of cabozantinib was disclosed in WO2010083414 application. WO2010083414 discloses that the tartrate salt of cabozantinib has low crystallinity, low solubility and is hygroscopic. WO2018218233 application describes other cabozantinib salts and solid forms thereof.
[0007] Cabozantinib and its salts described in the prior art have poor solubility. There remains a need to prepare cabozantinib salts and solid forms thereof having improved solubility, crystallinity and stability compared to the cabozantinib salts disclosed in the prior art.
[0008] Brief description of the invention
[0009] The present invention relates to a solid form of L-(+)-tartrate of cabozantinib and a method for preparing the same.
[0010] BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 Depicted is the X-ray powder diffraction pattern (XRPD) of L-(+)-tartrate salt Form 1 of cabozantinib prepared according to Example 1 or Example 2.
[0012] Figure 2 Depicted is a DSC graph of Form 1 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 1 or Example 2.
[0013] Figure 3 The TGA spectrum of L-(+)-tartrate salt form 1 of cabozantinib prepared according to Example 1 or Example 2 is described.
[0014] Figure 4The X-ray powder diffraction pattern (XRPD) of Form 2 of L-(+)-tartrate salt of cabozantinib prepared according to Example 3 or Example 4 or Example 9 is described.
[0015] Figure 5 Depicted is a DSC graph of Form 2 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 3 or Example 4 or Example 9.
[0016] Figure 6 The TGA spectrum of Form 2 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 3 or Example 4 or Example 9 is described.
[0017] Figure 7 Depicted is the X-ray powder diffraction pattern (XRPD) of L-(+)-tartrate salt Form 3 of cabozantinib prepared according to Example 5 or Example 6 or Example 7.
[0018] Figure 8 Depicted is the DSC graph of Form 3 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 5 or Example 6 or Example 7.
[0019] Fig. 9 The TGA spectrum of Form 3 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 5 or Example 6 or Example 7 is described.
[0020] Fig.10 Depicted is the X-ray powder diffraction pattern (XRPD) of Form 4 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 8.
[0021] Fig.11 Depicted is the DSC graph of L-(+)-tartrate salt Form 4 of cabozantinib prepared according to Example 8.
[0022] Fig.12 Depicted is the TGA spectrum of Form 4 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 8.
[0023] Fig.13 The NMR spectrum of Form 1 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 1 or Example 2 is described.
[0024] Fig.14 The NMR spectrum of Form 2 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 3 or Example 4 is described.
[0025] Fig.15 The NMR spectrum of Form 3 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 5 or Example 6 or Example 7 is described.
[0026] Fig.16 The NMR spectrum of Form 4 of the L-(+)-tartrate salt of cabozantinib prepared according to Example 8 is depicted.
[0027] Fig.17 Depicted is the X-ray powder diffraction pattern (XRPD) of Form 2A of the L-(+)-tartrate salt of cabozantinib prepared according to Example 9.
[0028] Fig.18 Depicted is the DSC graph of Form 2A of the L-(+)-tartrate salt of cabozantinib prepared according to Example 9.
[0029] Fig.19 Depicted is a TGA graph of Form 2A of the L-(+)-tartrate salt of cabozantinib prepared according to Example 9. DETAILED DESCRIPTION OF THE INVENTION
[0031] The present invention relates to L-(+)-tartrate of cabozantinib, its solid forms (form 1, form 2, form 3, form 4) and preparation methods thereof. Contrary to the teaching of WO2010083414 application, the L-(+)-tartrate of cabozantinib according to the present invention shows good crystallinity, improved solubility and low hygroscopicity.
[0032] The form 1 of the L-(+)-tartrate of cabozantinib can be characterized by an XRPD pattern with 2θ values of 3.9°, 13.5°, 14.8° and 23.1° 2θ (± 0.2 2θ). Solid form 1 can also be characterized by an XRPD pattern with 2θ values of 3.9°, 6.7°, 9.2°, 13.5°, 14.8°, 15.5° and 23.1° 2θ (± 0.2 2θ). The solid form can also be further characterized by the XRPD pattern described in the following table:
[0033]
[0034]
[0035] Solid form 1 can also be obtained by Figure 1 The solid form can be characterized by the XRPD pattern shown. Figure 2 The DSC pattern shown is further characterized. The solid form can be Figure 3 The solid form can also be characterized by the TGA pattern shown. Fig.13 The NMR spectrum is shown.
[0036] The solid form 1 of L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0037] a. mixing cabozantinib with a mixture of tetrahydrofuran and 2.5-10% water (volume %) at a temperature of 55°C to 65°C;
[0038] b. cooling the mixture at a temperature of 35°C to 45°C;
[0039] c. Add L-(+)-tartaric acid;
[0040] d. cooling the mixture to a temperature of 20°C to 25°C;
[0041] e. Isolating the solid form.
[0042] The concentration of cabozantinib in a mixture of tetrahydrofuran and water can be between 0.08g / mg and 1.3g / ml. Adding 2.5-10% water (volume %) to tetrahydrofuran significantly improves the solubility of cabozantinib in the mixture. The molar ratio of cabozantinib to L-(+)-tartaric acid can be between 1:1 and 1:1.2. Cabozantinib is mixed with a mixture of tetrahydrofuran and water at a temperature of 55°C to 65°C. The mixture is cooled to a temperature of 35°C to 45°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added in solid form or in the form of an aqueous solution of L-(+)-tartaric acid in a suitable solvent such as tetrahydrofuran. The mixture is cooled to a temperature of 20°C to 25°C and stirred at this temperature for 15 to 30 hours to obtain a suspension. The suspension is filtered and dried, optionally under vacuum (1-10 kPa) at a temperature of 25°C to 45°C for 15 to 30 hours to provide a solid Form 1 of the L-(+)-tartrate salt of cabozantinib.
[0043] The solid form 1 of the L-(+)-tartrate salt of cabozantinib can also be prepared by a method comprising the following steps:
[0044] a. mixing cabozantinib with a mixture of tetrahydrofuran, ethyl acetate and 1.5-10% water (volume %), preferably at a temperature of 55 ° C to 65 ° C;
[0045] b. cooling the mixture preferably to a temperature of 35°C to 45°C;
[0046] c. Add L-(+)-tartaric acid,
[0047] d. Cooling the mixture to a temperature of 20-25°C;
[0048] e. Isolating the solid form.
[0049] The volume ratio of tetrahydrofuran to ethyl acetate can be between 1:1 and 1:1.2. The molar ratio between cabozantinib and L-(+)-tartaric acid can be between 1:1 and 1:1.2. The concentration of cabozantinib in a mixture of tetrahydrofuran, ethyl acetate and water can be between 0.03g / ml and 0.07g / ml. Adding 1.5-10% water (volume %) to a mixture of tetrahydrofuran and ethyl acetate can significantly increase the solubility of cabozantinib in the mixture. Cabozantinib is preferably added to a mixture of tetrahydrofuran, ethyl acetate and water at a temperature of 55°C to 65°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent.
[0050] The mixture is cooled, preferably to a temperature of 20° C.-25° C., and stirred at this temperature for 8 to 15 hours to obtain a suspension. The suspension is filtered off and the solid obtained can optionally be dried.
[0051] The solid form 2 of the L-(+)-tartrate of cabozantinib can be characterized by an XRPD spectrum with 2θ values of 12.2°, 19.4°, 22.2° and 23° 2θ (± 0.2 2θ). The solid form 2 can also be characterized by an XRPD pattern with 2θ values of 4.4°, 8.5°, 12.2°, 14.0°, 19.4°, 22.2° and 23.0° 2θ (± 0.2 2θ). The solid form can be further characterized by the XRPD pattern described in the following table:
[0052] Angle (2θ) strength(%) Angle (2θ) strength(%) Angle (2θ) strength(%) 4.4 34.9 17.0 38.7 25.7 55.3 6.0 10.9 17.5 33.4 26.0 48.2 8.2 14.5 17.9 18.1 26.8 49.8 8.5 41.1 19.4 55.1 27.2 62.9 8.7 31.5 19.9 31.5 27.7 41.7 11.2 15.4 20.8 32.4 28.4 33.8 12.0 62.4 21.4 47.7 29.0 35.2 12.2 100.0 21.8 31.2 30.2 25.4 14.0 38.8 22.2 60.4 31.9 21.4 14.4 28.1 23.0 53.5 33.2 22.5 14.9 14.0 23.7 53.5 34.0 21.6 16.1 21.6 24.5 73.3 16.4 31.8 24.8 53.8
[0053] Solid Form 2 can also be obtained by Figure 4 The solid form can be further characterized by the XRPD pattern shown. Figure 5 The solid form can be further characterized by the DSC spectrum shown. Figure 6 The solid form can also be characterized by the TGA spectrum shown in Fig.14 The NMR spectrum characterization.
[0054] The solid form 2 of the L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0055] a. mixing cabozantinib with a mixture of tetrahydrofuran and methanol;
[0056] b. Add L-(+)-tartaric acid,
[0057] c. cooling the mixture;
[0058] d. isolating the solid form.
[0059] The volume ratio between tetrahydrofuran and methanol can be between 1.1:1 and 1.4:1. The molar ratio of cabozantinib to L-(+)-tartaric acid can be between 1:1 and 1:1.6, preferably 1:1 to 1:1.2. The concentration of cabozantinib in the mixture of tetrahydrofuran and methanol can be between 0.06g / ml and 0.1g / ml. Cabozantinib is preferably mixed with the mixture of tetrahydrofuran and methanol at a temperature of 60°C to 70°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent.
[0060] The mixture is cooled, preferably to a temperature of 20° C.-25° C., and stirred at this temperature for 5 to 10 hours to obtain a suspension. The suspension is filtered off and the solid obtained is optionally dried.
[0061] The solid form 2 of the L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0062] a. mixing cabozantinib with a mixture of tetrahydrofuran, toluene and 2.5-10% (volume %) water;
[0063] b. Add L-(+)-tartaric acid,
[0064] c. cooling the mixture;
[0065] d. isolating the solid form.
[0066] The volume ratio of tetrahydrofuran to toluene can be between 1:1 and 1:1.2. The concentration of cabozantinib in a mixture of tetrahydrofuran, toluene and water can be between 0.06g / ml and 0.1g / ml. Adding 2.5-10% (volume %) of water to a mixture of tetrahydrofuran and toluene can significantly increase the solubility of cabozantinib in the mixture. The molar ratio between cabozantinib and L-(+)-tartaric acid can be 1:1 to 1:1.6, preferably 1:1 to 1:1.2. Preferably, cabozantinib is mixed with a mixture of tetrahydrofuran, toluene and water at a temperature of 55°C to 65°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent. The mixture is preferably cooled to a temperature of 20°C-25°C and stirred at this temperature for 8-15 hours to provide a suspension. The suspension was filtered off and the resulting solid was dried in air for 8-15 hours.
[0067] Solid Form 2 can also be prepared by drying L-(+)-tartrate solid Form 2A of cabozantinib, preferably at a temperature of 60° C. to 90° C. for 3 to 10 hours.
[0068] The solid form 3 of the L-(+)-tartrate of cabozantinib can be characterized by an XRPD spectrum with 2θ values of 10.2°, 13.5°, 15.4° and 22.8° 2θ (± 0.2 2θ). The solid form 3 can also be characterized by an XRPD pattern with 2θ values of 3.9°, 8.4°, 10.2°, 12.8°, 13.5°, 15.4°, 22.8° and 25.9° 2θ (± 0.2 2θ). The solid form can be further characterized by the XRPD pattern described in the following table:
[0069] Angle (2θ) strength(%) Angle (2θ) strength(%) Angle (2θ) strength(%) 3.9 27.0 19.6 12.1 27.0 12.2 6.8 23.5 19.9 7.8 27.3 28.5 7.8 10.6 20.5 22.9 27.9 6.7 8.4 26.2 20.9 27.2 28.1 6.7 10.2 33.6 21.3 12.0 28.6 7.4 10.8 7.8 21.8 14.4 29.1 14.7 12.0 8.6 22.1 20.8 29.3 9.0 12.7 25.0 22.8 63.2 30.0 11.6 13.5 100.0 23.2 42.0 30.8 8.8 15.4 59.0 23.5 25.9 31.9 9.3 15.6 17.3 24.1 10.7 32.5 4.8 15.8 14.3 24.8 12.9 32.9 8.7 16.8 13.8 25.0 15.9 33.1 8.1 18.3 15.2 25.2 16.9 33.5 7.2 18.5 33.3 25.9 65.3 33.6 7.6 19.3 13.2 26.2 23.5 34.1 6.6
[0070] Solid form 3 can also be obtained by Figure 7 The solid form can also be characterized by the XRPD pattern shown. Figure 8 The solid form can also be characterized by the DSC spectrum shown. Fig. 9 The solid form can also be characterized by the TGA spectrum shown. Fig.15 NMR spectrum characterization shown.
[0071] The solid form 3 of the L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0072] a. mixing cabozantinib with a mixture of tetrahydrofuran and 2.5-10% water (volume %), preferably at a temperature of 55 ℃ and 65 ℃;
[0073] b. Add L-(+)-tartaric acid,
[0074] c. Cooling the mixture preferably to a temperature of 20°C-25°C;
[0075] d. isolating the solid form.
[0076] The concentration of cabozantinib in a mixture of tetrahydrofuran and water can be between 0.08 g / ml and 0.11 g / ml. Adding 2.5-10% water (volume %) to tetrahydrofuran can significantly increase the solubility of cabozantinib in the mixture. The molar ratio between cabozantinib and L-(+)-tartaric acid can be between 1:1 and 1:1.2. Preferably, cabozantinib is mixed with a mixture of tetrahydrofuran and water at a temperature of 55°C to 65°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent. The mixture is preferably cooled to a temperature of 20°C and 25°C and stirred at this temperature for 8 to 15 hours to provide a suspension. The suspension is filtered out, and the obtained solid can be optionally dried.
[0077] The solid form 3 of the L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0078] a. mixing cabozantinib with a mixture of tetrahydrofuran, acetone and 2.5-10% water (volume %), preferably at a temperature of 55 ℃ and 65 ℃;
[0079] b. Add L-(+)-tartaric acid,
[0080] c. Cooling the mixture preferably to a temperature of 20°C-25°C;
[0081] d. isolating the solid form.
[0082] The concentration of cabozantinib in a mixture of tetrahydrofuran, acetone and water can be between 0.07 g / ml and 0.11 g / ml. Adding 2.5-10% water (volume %) to a mixture of tetrahydrofuran and acetone can significantly increase the solubility of cabozantinib in the mixture. The molar ratio between cabozantinib and L-(+)-tartaric acid can be 1:1 to 1:1.6, preferably 1:1 to 1:1.2. Preferably, cabozantinib is mixed with a mixture of tetrahydrofuran, acetone and water at a temperature of 55°C to 65°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent. The mixture is cooled preferably to a temperature of 20°C-25°C, and stirred at this temperature for 8 to 15 hours to provide a suspension. The suspension is filtered out, and the obtained solid can be optionally dried.
[0083] The solid form 3 of the L-(+)-tartrate salt of cabozantinib can also be prepared by a method comprising the following steps:
[0084] a. mixing cabozantinib with a mixture of tetrahydrofuran, ethanol and 1.5-10% water (volume %), preferably at a temperature of 55 ℃ and 65 ℃;
[0085] b. Add L-(+)-tartaric acid,
[0086] c. Cooling the mixture preferably to a temperature of 20°C-25°C;
[0087] d. isolating the solid form.
[0088] The concentration of cabozantinib in a mixture of tetrahydrofuran, ethanol and water can be between 0.07 g / ml and 0.11 g / ml. The volume ratio between tetrahydrofuran and ethanol can be between 1:1 and 1.2:1. Adding 2.5-10% water (volume %) to a mixture of tetrahydrofuran and ethanol can significantly increase the solubility of cabozantinib in the mixture. The molar ratio between cabozantinib and L-(+)-tartaric acid can be from 1:1 to 1:1.6, preferably from 1:1 to 1:1.2. Preferably, cabozantinib is mixed with a mixture of tetrahydrofuran, ethanol and water at a temperature of 55°C to 65°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent. The mixture is stirred at a temperature of 55°C-65°C for 20-60 minutes. The mixture is cooled, preferably to a temperature of 20° C.-25° C., and stirred at this temperature for 8 to 15 hours to provide a suspension. The suspension is filtered off, and the solid obtained can optionally be dried.
[0089] The solid form 4 of the L-(+)-tartrate of cabozantinib can be characterized by an XRPD pattern with 2θ values of 8.6°, 12.3°, 25.8° and 26.2° 2θ (± 0.2 2θ). The solid form 4 can also be characterized by an XRPD pattern with 2θ values of 8.6°, 12.3°, 17.3°, 23.3°, 25.8° and 26.2° 2θ (± 0.2 2θ). The solid form can be further characterized by the XRPD pattern described in the following table:
[0090]
[0091]
[0092] Solid form 4 can also be obtained by Fig.10 The solid form can also be characterized by the XRPD pattern shown. Fig.11 The solid form can also be characterized by the DSC spectrum shown. Fig.12 The solid form can also be characterized by the TGA spectrum shown. Fig.16 NMR spectrum characterization shown.
[0093] The solid form 4 of the L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0094] a. mixing cabozantinib with a mixture of anisole, butanol and 2.5-10% water (volume %), preferably at a temperature of 55 ℃ to 65 ℃;
[0095] b. Add L-(+)-tartaric acid,
[0096] c. Cooling the mixture preferably to a temperature of 20°C-25°C;
[0097] d. isolating the solid form.
[0098] The concentration of cabozantinib in a mixture of anisole, butanol and water can be between 0.07 g / ml and 0.11 g / ml. The volume ratio of anisole to butanol can be between 0.8:1 and 1.2:1. Adding 2.5-10% water (volume %) to a mixture of anisole and butanol can significantly increase the solubility of cabozantinib in the mixture. The molar ratio between cabozantinib and L-(+)-tartaric acid can be from 1:1 to 1:1.6, preferably from 1:1 to 1:1.2. Preferably, cabozantinib is mixed with a mixture of anisole, butanol and water at a temperature of 55°C to 65°C. L-(+)-tartaric acid is added to the mixture. L-(+)-tartaric acid can be added as a solid or in a solution in a suitable solvent. The mixture is stirred at a temperature of 55°C-65°C for 20-60 minutes. The mixture is cooled, preferably to a temperature of 20°C-25°C, and stirred at this temperature for 8-15 hours to provide a suspension. The suspension is filtered off and the solid obtained can be optionally dried.
[0099] The solid form 2A of the L-(+)-tartrate of cabozantinib can be characterized by an XRPD spectrum with 2θ values of 12.2°, 19.4°, 21.0°, 22.2°, 23.0°, and 24.0° 2θ (± 0.2 degrees 2θ). The solid form 2A can also be characterized by an XRPD spectrum with 2θ values of 12.2°, 18.5°, 19.4°, 21.0°, 22.2°, 23.0°, 24.0°, and 31.4° 2θ (± 0.2 degrees 2θ). The solid form can be further characterized by the XRPD patterns described in the following table:
[0100] Angle (2θ) strength(%) Angle (2θ) strength(%) Angle (2θ) strength(%) 4.4 34.9 17.9 18.1 26.8 49.8 6.0 10.9 18.5 19.2 27.2 62.9 8.2 14.5 19.4 55.1 27.7 41.7 8.5 41.1 19.9 31.5 28.4 33.8 8.7 31.5 20.8 32.4 29.0 35.2 11.2 15.4 21.0 29.1 30.2 25.4 12.0 62.4 21.4 47.7 31.4 22.9 12.2 100.0 21.8 31.2 31.9 21.4 13.1 12.5 22.2 60.4 32.6 22.0 14.0 38.8 23.0 53.5 33.2 22.5 14.4 28.1 23.7 53.5 33.9 21.4 14.9 14.0 24.0 32.6 34.0 21.6 16.1 21.6 24.5 73.3 16.4 31.8 24.8 53.8 17.0 38.7 25.7 55.3 17.5 33.4 26.0 48.2
[0101] Solid Form 2A can also be obtained by Fig.17 The solid form can be further characterized by the XRPD pattern shown. Fig.18 The solid form can be further characterized by the DSC spectrum shown. Fig.19 TGA spectrum characterization shown.
[0102] The solid form 2A of the L-(+)-tartrate salt of cabozantinib can be prepared by a method comprising the following steps:
[0103] a. mixing cabozantinib with a mixture of tetrahydrofuran, butyl acetate and dimethylformamide to obtain a mixture 1;
[0104] b. dissolving L-(+)-tartaric acid with methanol and butyl acetate, preferably stirring at a temperature of 40 ℃ to 60 ℃ to obtain a mixture 2;
[0105] c. Add mixture 1 to mixture 2;
[0106] d. stirring the resulting mixture;
[0107] e. cooling the mixture to a temperature of 10°C to 30°C;
[0108] f. Isolation of the solid Form 2A.
[0109] The molar ratio between cabozantinib and L-(+)-tartaric acid may be between 1:1 and 1:1.6.
[0110] The concentration of cabozantinib in a mixture of tetrahydrofuran, butyl acetate and dimethylformamide may be between 0.1 g / g and 0.3 g / g. The ratio (wt / wt) between tetrahydrofuran, butyl acetate and dimethylformamide may be between 1:0.7:0.3 and 1:1.5:0.8. Cabozantinib is mixed with a mixture of tetrahydrofuran, butyl acetate and dimethylformamide to obtain mixture 1. The concentration of L-(+)-tartaric acid in methanol and butyl acetate may be between 0.08 g / g and 0.3 g / g. The ratio (wt / wt) between methanol and butyl acetate may be between 1:0.3 and 1:0.6. L-(+)-tartaric acid is mixed with a mixture of methanol and butyl acetate, and the mixture is heated to a temperature of 40°C to 60°C and may be stirred at this temperature for 30 to 180 minutes to obtain mixture 2.
[0111] Mixture 1 is added to mixture 2 at a temperature of 40°C-60°C. Mixture 1 can be added in several portions, for example, in 1 portion, 2 portions, 3 portions, 4 portions, 5 portions, or 6 portions. The resulting mixture is stirred at a temperature of 40°C to 60°C for 2 to 10 hours. The mixture is then cooled to a temperature of 10°C to 30°C and stirred at this temperature for 2 to 10 hours. The obtained suspension is filtered, and the obtained solid is washed with methanol heated to 35°C-45°C to provide a solid form 2A of the L-(+)-tartrate of cabozantinib.
[0112] The present invention is further described with reference to the following examples. Example
[0113] Nuclear magnetic resonance spectroscopy (NMR) was performed using an Avance III 400 MHz NMR spectrometer.
[0114] The DCS graph was obtained using the following conditions: 10°C / min->300°C
[0115] XRPD spectra were obtained using the following measurement conditions:
[0116] Panalytical Empyreandiffractometer with Θ / 2Θ geometry (transmission mode) equipped with PixCell 3D detector;
[0117]
[0118]
[0119] Example 1: L-(+)-Tartrate Salt of Cabozantinib, Form 1
[0120] At 60 ° C, 2 grams of cabozantinib were mixed with a mixture of 20 ml of tetrahydrofuran and 0.6 ml of water. The mixture was cooled to 40 ° C, and a mixture of 0.599 grams of L-(+)-tartaric acid in 2 ml of tetrahydrofuran was added. The mixture was cooled to a temperature of 20 ° C and 25 ° C, and stirred at this temperature for 24 hours. The obtained suspension was filtered out, and the obtained solid was dried in vacuum (10kPa) at 40 ° C for 24 hours to obtain 1.4g of the solid form 1 of the L-(+)-tartrate of cabozantinib.
[0121] Example 2: L-(+)-Tartrate Salt of Cabozantinib, Form 1
[0122] 0.5g of cabozantinib was mixed with a mixture of 5ml tetrahydrofuran, 5ml ethyl acetate and 0.15ml water. The mixture was heated to 60°C and 0.15g of L-(+)-tartaric acid was added. The mixture was cooled to a temperature of 20-25°C in 10 hours. The obtained suspension was filtered, and the obtained solid was washed with a mixture of 1ml tetrahydrofuran and 1ml ethyl acetate, and dried in air for 12 hours to obtain a solid form 1 of the L-(+)-tartrate of 0.622g of cabozantinib.
[0123] Example 3: L-(+)-Tartrate Salt of Cabozantinib, Form 2
[0124] A mixture of 0.5 g of cabozantinib and 3 mL of tetrahydrofuran, 3 mL of toluene and 0.5 mL of water was mixed at 60 °. 0.15 g of L-(+)-tartaric acid was added to the mixture. The mixture was stirred at 60 ° C for 20 minutes and then cooled to a temperature of 20 ° C to 25 ° C in 8 to 12 hours. The obtained suspension was filtered out, the obtained solid was washed with 1 ml of toluene, and dried in air for 12 hours to obtain 0.64 g of the solid form 2 of the L-(+)-tartrate of cabozantinib.
[0125] Example 4: L-(+)-Tartrate Salt of Cabozantinib, Form 2
[0126] 0.5g of cabozantinib is mixed with a mixture of 3.5ml tetrahydrofuran and 3ml methanol, and the mixture is heated to reflux (bath 70°C). 0.15g of L-(+)-tartaric acid is added to the mixture. The mixture is cooled to a temperature of 20°C to 25°C for 12 hours. The obtained suspension is diluted with a mixture of 1ml THF and 1ml MeOH to improve filterability. The obtained suspension is filtered out. The obtained solid is washed with 1mL methanol MeOH and air dried at 20-25°C for 12 hours to obtain a solid form 2 of L-(+)-tartrate of cabozantinib, with a yield of 88%.
[0127] Example 5: L-(+)-Tartrate Salt of Cabozantinib, Form 3
[0128] At 60 ° C, 0.5g of cabozantinib was mixed with a mixture of 5ml tetrahydrofuran and 0.15ml water. 0.15g of L-(+)-tartaric acid was added to the mixture. The mixture was cooled to 20-25 ° C in 10 hours. The resulting suspension was filtered out. The obtained solid was washed with 1mL tetrahydrofuran THF and dried in air at 20-25 ° C for 12 hours to obtain a solid form 3 of L-(+)-tartrate of cabozantinib with a yield of 91%.
[0129] Example 6: L-(+)-Tartrate Salt of Cabozantinib, Form 3
[0130] At 60°C, 0.5g of cabozantinib was mixed with a mixture of 3ml tetrahydrofuran, 3ml acetone and 0.15ml water. 0.15g of L-(+)-tartaric acid was added to the mixture. The mixture was cooled to a temperature of 20°C to 25°C for 10 hours. The resulting suspension was filtered out. The obtained solid was washed with a mixture of 1ml tetrahydrofuran and 1ml acetone and air dried at 20-25°C for 12 hours to obtain 0.577g of the solid form 3 of the L-(+)-tartrate of cabozantinib.
[0131] Example 7: L-(+)-Tartrate Salt of Cabozantinib, Form 3
[0132] At 60 ℃, 0.5g of cabozantinib was mixed with a mixture of 3ml tetrahydrofuran, 3ml ethanol and 0.5ml water. 0.15g of L-(+)-tartaric acid was added to the mixture. The mixture was stirred at 60 ℃ for 30 minutes and then cooled to 20-25 ℃ in 10 hours. The resulting suspension was filtered out. The solid obtained was washed with a mixture of 0.5ml tetrahydrofuran and 0.5ml ethanol and EtOH, and air dried at 20-25 ℃ for 12 hours to obtain 0.61g of the solid form 3 of the L-(+)-tartrate of cabozantinib.
[0133] Example 8: L-(+)-Tartrate Salt of Cabozantinib, Form 4
[0134] At 70 ° C, 0.5g of cabozantinib was mixed with a mixture of 3ml anisole, 3ml butanol and 0.15ml water. 0.15g of L-(+)-tartaric acid was added to the mixture. Stirred at 60 ° C for 20 minutes, then cooled to ambient temperature within 10 hours. The obtained suspension was filtered out. The obtained solid was washed with 1mL butanol and dried in 20-25 ° C of air for 12 hours to obtain 0.622g of the solid form 4 of the L-(+)-tartrate of cabozantinib.
[0135] Example 9: L-(+)-Tartrate Salt of Cabozantinib, Form 2A and Form 2
[0136] 3.8g L-(+)-tartaric acid is dissolved in 22g MeOH and 10g n-butyl acetate. The mixture is heated to 55°C and stirred at this temperature for 60 minutes. At 55°C, a mixture of 8.5g cabozantinib, 20g tetrahydrofuran, 20g n-butyl acetate and 10g dimethylformamide is added to the mixture. The resulting mixture is stirred at 55°C for 3 hours, cooled to 25°C and stirred at 25°C for 2 hours. The obtained suspension is filtered and washed with 40g methanol heated to 40°C to obtain L-(+)-tartrate of cabozantinib, Form 2A with a yield of 87%.
[0137] The obtained Form 2A was dried at 85°C for 5 hours to afford the L-(+)-tartrate salt Form 2 of cabozantinib in quantitative yield.
[0138] Example 10: Solubility of L-(+)-tartrate salt of cabozantinib
[0139] The solubility of the L-(+)-tartrate salt of Cabozantinib was measured and is summarized in the following table:
[0140]
[0141] Samples were prepared by dissolving 12 mg of sample in 50 ml of the relevant solvent.
[0142] The samples were mixed at 37°C for 60 minutes and measured by HPLC method.
[0143] It can be concluded that the solubility of the prepared solid form of L-(+)-tartrate of cabozantinib is improved compared to the solid form described in WO2010083414 application. The prepared solid form of cabozantinib L-(+)-tartrate shows good crystallinity and low hygroscopicity.
Claims
1. L-(+)-tartrate salt of cabozantinib.
2. A solid form of a compound according to claim 1.
3. A solid form according to claim 2, form 1, characterized in that The XRPD pattern had 2Θ values of 3.9°, 13.5°, 14.8°, and 23.1° degrees 2Θ (± 0.2° 2Θ).
4. A solid form according to claim 3, characterised in that The XRPD pattern had 2Θ values of 3.9°, 6.7°, 9.2°, 13.5°, 14.8°, 15.5°, and 23.1° degrees 2Θ (± 0.2 degrees 2Θ).
5. A solid form according to claim 2, Form 2, characterized in that The XRPD pattern had 2Θ values of 12.2°, 19.4°, 22.2°, and 23° degrees 2Θ (± 0.2° 2Θ).
6. A solid form according to claim 5, characterised in that The XRPD pattern had 2Θ values of 4.4°, 8.5°, 12.2°, 14.0°, 19.4°, 22.2°, and 23.0° degrees 2Θ (± 0.2 degrees 2Θ).
7. The method for preparing a solid form according to claim 5 or 6, comprising: a. mixing cabozantinib with a mixture of tetrahydrofuran and methanol, preferably at a temperature of 60 ℃ to 70 ℃; b. Add L-(+)-tartaric acid; c. Cooling the mixture preferably to a temperature of 20°C-25°C; d. isolating the solid form.
8. A method for preparing a solid form according to claim 5 or 6, comprising drying a solid Form 2A of the L-(+)-tartrate salt of cabozantinib, wherein the solid Form 2A is characterized by an XRPD pattern having 2θ values of 12.2°, 19.4°, 21.0°, 22.2°, 23.0° and 24.0° degrees 2θ (±0.2° 2θ).
9. The method for preparing a solid form according to claim 5 or 6, comprising: a. mixing cabozantinib with a mixture of tetrahydrofuran, butyl acetate and dimethylformamide to obtain a mixture 1; b. dissolving L-(+)-tartaric acid with methanol and butyl acetate, and stirring the mixture preferably at a temperature of 40 ℃ to 60 ℃ to obtain a mixture 2; c. Add mixture 1 to mixture 2; d. stirring the resulting mixture; e. Cooling the mixture preferably to a temperature of 10 ℃ -30 ℃; f. isolating the solid form 2A; g. Drying the solid Form 2A.
10. The solid form according to claim 2, form 3, characterized in that The XRPD pattern had 2Θ values of 10.2°, 13.5°, 15.4°, and 22.8° degrees 2Θ (± 0.2 degrees 2Θ).
11. A solid form according to claim 10, characterised in that The XRPD pattern had 2Θ values of 3.9°, 8.4°, 10.2°, 12.8°, 13.5°, 15.4°, 22.8°, and 25.9° degrees 2Θ (± 0.2 degrees 2Θ).
12. A solid form according to claim 2, form 4, characterized in that The XRPD pattern had 2Θ values of 8.6°, 12.3°, 25.8°, and 26.2° degrees 2Θ (± 0.2 degrees 2Θ).
13. A solid form according to claim 12, characterised in that The XRPD pattern had 2Θ values of 8.6°, 12.3°, 17.3°, 23.3°, 25.8°, and 26.2° degrees 2Θ (± 0.2 degrees 2Θ).
